News

Roanoke labs project awaits final budget approval

The intended site for 30,000 square feet of lab space is a Carilion-owned building on South Jefferson Street.

An estimated 30,000 square feet of shared lab space could go online in Roanoke within a year and a half, assuming that the General Assembly votes Wednesday to approve a compromise budget that includes nearly $16 million in state funding for the project.
The lab initiative, which was announced in December and also includes a smaller lab facility at the Virginia Tech Corporate Research Center, is designed to meet what economic development and technology leaders have for years seen as a critical need: room for researchers and entrepreneurs – especially those in the region’s burgeoning life sciences cluster – to do their work.

The intended site in Roanoke is a building on South Jefferson Street that’s owned by Carilion Clinic and is centrally located to biomedical and health science research that’s already underway in the city: It’s less than a half-mile from either the campus that houses the Virginia Tech Carilion School of Medicine and the Fralin Biomedical Research Institute or the downtown Roanoke home of RAMP, a regional technology business accelerator.

The building, which formerly housed some of Carilion’s pediatric services and is now mostly vacant, must still be fully evaluated for its suitability for the project, Carilion CFO Don Halliwill said Tuesday.

Once the General Assembly approves the budget – and the governor signs off on it – the project partners will have $15.7 million to put toward renovating the building, work that is expected to take 16 to 18 months, according to Brett Malone, president and CEO of the Corporate Research Center. The city of Roanoke is contributing another $1.9 million to the project, said Marc Nelson, the city’s director of economic development.

Read more here.

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business